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Abstract
Hepatitis C virus infection leads to a high rate of chronicity. Mechanisms of viral clearance and persistence are still poorly
understood. In this study, hepatic gene expression analysis was performed to identify any molecular signature associated
with the outcome of hepatitis C virus (HCV) infection in chimpanzees. Acutely HCV-infected chimpanzees with self-limited
infection or progression to chronicity were studied. Interferon stimulated genes were induced irrespective of the outcome
of infection. Early induction of a set of genes associated with cell proliferation and immune activation was associated with
subsequent viral clearance. Specifically, two of the genes: interleukin binding factor 3 (ILF3) and cytotoxic granule-
associated RNA binding protein (TIA1), associated with robust T-cell response, were highly induced early in chimpanzees
with self-limited infection. Up-regulation of genes associated with CD8+ T cell response was evident only during the
clearance phase of the acute self-limited infection. The induction of these genes may represent an initial response of cellular
injury and proliferation that successfully translates to a ‘‘danger signal’’ leading to induction of adaptive immunity to control
viral infection. This primary difference in hepatic gene expression between self-limited and chronic infections supports the
concept that successful activation of HCV-specific T-cell response is critical in clearance of acute HCV infection.
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Introduction
Since the identification of hepatitis C virus (HCV) in the late
1980s, HCV infection has been recognized as a growing public
health problem in the world. It is estimated that about 200 million
people are chronically infected [1]. No HCV vaccines are
available to date and only a subset of patients respond to current
interferon-based treatment [1]. Much research effort has been
focused on understanding the mechanisms of infection, persistence
and clearance of HCV. Studies on hepatic gene expression in
chimpanzees and humans have revealed intriguing differences
between acute resolving and chronic HCV infections [2–6]. In the
chimpanzee model, HCV infection induces type I IFN response
and activation of a large number of interferon stimulated genes
(ISGs) in the liver [2,6,7]. However, hepatic induction of type I
IFN occurred in all animals irrespective of the outcome of
infection [6,8]. Thus, type I IFN may restrict excessive viral
replication in the early phase of infection but does not seem to play
a major role in subsequent viral clearance. Similar to experimen-
tally infected chimpanzees, gene expression analysis of percutane-
ous liver biopsies in HCV infected humans demonstrated
increased ISG expression, suggesting an ongoing host cellular
response to viral infection [4]. It is not well understood why HCV
is not cleared from these individuals despite the activation of
potent antiviral ISGs. It is possible that in these individuals with
viral persistence, the cellular response to IFN is inefficient
compared to those who clear the virus. Weak induction of the
ISG antiviral state coupled with an ineffective cellular immune
response could therefore promote chronicity [3].
Studies of temporal changes in gene expression are central to
understanding viral clearance, persistence and hepatic injury in
chronic HCV infection. The intrahepatic T cell response to HCV
correlates with control of acute infection [7]. Cytokine and
immunomodulatory genes, generally known to be chemotactic
and/or stimulatory to various immune cells were observed to be
induced within the first 6 to 8 weeks after infection [2]. Viral
clearance is associated with a vigorous HCV-specific T-cell
response in the liver with both cytotoxic and non-cytotoxic
effector functions. However HCV persists in the majority of
acutely infected patients. The mechanisms leading to the failure of
HCV-specific T-cell response and viral persistence are highly
complex and still not fully understood. Therefore it is important to
compare the spectrum and magnitude of hepatic gene expression
in individuals who spontaneously clear infection and those who
progress to chronicity. In this study we examined the host response
to HCV infection by applying gene expression profiling of serial
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3442liver biopsies during acute HCV infection and identified unique
gene expression patterns that are associated with specific outcomes
of infection.
Results
Hepatic gene expression during early stage of self-
limited infection
To identify differentially expressed hepatic genes associated with
early stages of HCV infection, a database of expression levels was
generated and queried for genes whose expression was outside a
calculated 99% confidence interval at different times. Using this
confidence interval, 1% of genes with the greatest-fold change or
least-fold change are defined as significantly up- or down-regulated
(see Materials and Methods). For chimpanzee X0190 with self-
limited infection, 347 genes were induced above the confidence
interval (.1.9-fold change) at 4 weeks post-infection. Some of the
induced genes were related to antiviral and/or type I interferon
response, consistent with ongoing HCV infection. To refine our
search and to further identify genes specifically associated with the
early phase of infection, the database of expression levels for
X0190 was queried again for genes above the confidence interval
at two time points, weeks 4 and 6 post-infection (.1.9- and .2.1-
fold induction), and below the confidence interval at weeks 13 and
40 (,2.2-, and ,2.4-fold induction) when the chimpanzee had
cleared the infection. By using these criteria, 22 genes were
significantly up-regulated, 9 of which are known to be induced by
type I interferon (Table 1). The remaining 13 genes are classified
as Cellular Immune Response Related or Cell Growth/Signal
Transduction Related.
Comparison of hepatic gene expression during self-
limited and persistent infections
To determine whether a different pattern of gene expression is
observed between infected chimpanzees in this subset of genes,
biopsy samples from two persistently infected chimpanzees X0234
and X0142 were compared to chimpanzee X0190 (Table 1).
Within the first 8 weeks of infection, a large number of type I
interferon stimulated genes (ISGs) were strongly up-regulated in all
chimpanzees. Type I interferon induced genes are the first line of
innate defense against viral infection and also function to prime
and modulate adaptive immune response. A qualitative or
quantitative difference of ISG induction could not be correlated
with persistence or clearance. However several genes related to
cellular immune response and cell growth/signal transduction,
such as ILF3, TIA1, FOSB, JUN, ID2, were differentially induced
in chimpanzee X0190.
At later time points for X0190, none of the type I interferon
response genes were significantly upregulated, consistent with the
clearance of viremia and resolution of infection. Interestingly, a
similar gene expression pattern was also observed for the
persistently infected chimps. In X0234, some of these genes that
were induced earlier returned to baseline at week 10, but became
elevated again at week 12 post-infection. It has been shown that
acutely infected chimpanzees and humans can have markedly
fluctuating levels of viremia during the acute phase, possibly
indicating transient control of viral infection [9–11]. This transient
control could explain the lack of continuous induction of ISGs at
certain time points. In particular, the viral level of X0234 at week
8 was 4000 genomes/mL, week 10 was 600 genomes/mL
(borderline detection), and week 12 was 7000 genomes/mL.
Additional biopsy samples from one of these animals, X0142, were
collected at much later time points during the chronic phase
(Fig. 1). Up-regulation of many ISGs was again observed,
suggesting the establishment of chronic infection. This observation
is consistent with previous publications [3,6].
As an alternative approach to identify genes induced during the
early stage of infection that could be associated with clearance, the
average expression profile of persistently infected chimpanzees
(X0234 and X0140) was compared to the average expression
profile of chimp X0190 during weeks 4 and 6. We reasoned that
any difference between the two groups of animals, if significant,
might be more easily detected by averaging the gene expression
values during this time frame. Furthermore, we might identify a
different set of induced genes compared to our previous analysis
(e.g. genes whose fold-induction levels were within the confidence
interval for at least one time point but were on average higher
during the acute phase of infection).
During the first eight weeks of self limited infection (X1090) we
found 36 known genes induced 2.5-fold or greater over those
during persistent infection (X0234 and X0140). The averaged
ratios of induction are shown in Table 2. Six of these genes were
also found on the list of the previous analysis of chimpanzee
X0190 at weeks 4 and 6 (Table 1).
Hepatic gene expression during the clearance phase of
self-limited infection
To identify genes that may be specifically induced during viral
clearance in chimpanzee X0190, the database of expression levels
was queried for genes above the confidence interval at 13 weeks
post-infection (.2.2-fold induction) and below this interval at 4, 6
and 40 weeks (,1.9-, 2.1-, and 2.4-fold induction). Forty-four
genes were significantly up-regulated at 13 weeks (Table 3).
Twenty of these were associated with activation of cellular
immunity and as such were classified as Cellular Immune
Response-related. Consistent with the previous observation of
active HCV-specific T-cell response in biopsy specimens during
resolving infections, we found evidence for a vigorous immune
response involving induction of CD8+ T-cell markers (CD8
antigen and components of the T-cell receptor) and effectors of
CD8+ T cells (granzyme A and interferon-gamma) in X0190. The
remaining 25 genes significantly induced at 13 weeks could be
classified as Cell Growth/Signal Transduction-related (Table 3).
To discern additional differences between the self-limited and
chronically infected chimpanzees, the averaged expression profiles
of the two persistently infected chimpanzees (X0142 and X0234)
from weeks 10 to 12 were compared to those of chimpanzee
X0190 during clearance (week 13). We reason that viral clearance
may be associated with a distinct set of gene expression in the liver.
By comparing the gene expression profiles at about the same time
when the chimpanzee is undergoing viral clearance to those of
chimpanzee who is not could provide valuable insight into the
mechanism of viral clearance. During this phase, 20 known genes
of X0190 were induced 2.5-fold or greater over the average values
of the equivalent time points of X0142 and X0234 (Table 4). Of
these, 5 genes are also in Table 3.
Quantitative PCR confirmation of selected genes
To confirm the microarray data, TaqMan real-time PCR was
performed on selected genes from each analysis. For ISGs, GIP2
and IFIT1 were analyzed. Among the genes identified in Tables 1
and 2, ILF3, TIA1, ID2 and JUN were selected for quantitative
PCR. In addition, serial liver biopsy RNAs from another
chimpanzee that developed chronic infection after inoculation
with a different HCV strain (H77 1a) were analyzed. The data in
general support the microarray results. The ISG expression varied
among the chimpanzees, but showed no significant difference
between self-limited and chronic infections. The genes (ILF3,
Hepatic Gene Expression
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during the early phase of HCV infection between the two groups
were confirmed by quantitative PCR. Their expression levels were
10 to 100-fold higher in X0190 than those of other three
chimpanzees.
Discussion
HCV infection can lead to a high rate of chronicity, with 70–
80% of infected persons developing persistent infection [1]. The
mechanisms by which HCV establishes chronic infection have
been the subject of intense research. Failure of HCV-specific
immune response, particularly of the T cells, has been proposed as
the cause of chronicity [12,13]. Studies in humans and
chimpanzees have shown that T cell-mediated immunity is
important for viral clearance [14,15]. However, the pivotal
question remains as to how the host immune response fails during
the acute HCV infection so it can no longer control the virus,
resulting in persistent infection. Thus it is crucial to define the
molecular and cellular mechanisms by which the antiviral host
response is activated and regulated during the early stage of acute
HCV infection. Furthermore, because the major site of viral
tropism is the liver, it is essential to study these events in the liver.
One approach to elucidate this complicated process is to study the
global gene expression profile in the liver during the acute phase of
viral infection, and to discern unique patterns that are associated
with either viral clearance or progression to chronic infection.
We previously reported the infection of three chimpanzees with
an infectious HCV genotype 1b clone; one had acute self-limited
infection and the other two developed chronic infection [16]. We
reported that regardless of the outcome of infection, peripheral T-
cell responses were weak and comparable among the chimpanzees
during the course of infection; however, intrahepatic T-cell
response was not analyzed [17]. In this study, serial liver biopsies
were available in these chimpanzees and were used for cDNA
microarray analysis. Analysis of these gene expression patterns
revealed that a type I interferon response was induced during the
early phase (4–8 weeks) of infection in all chimpanzees regardless
of the outcome of infection. Various well-defined interferon
stimulated genes were up-regulated in all the liver samples. This
observation is consistent with previous studies describing that type
I interferon response is rapidly induced in the liver in response to
HCV infection [2,6].
Interestingly, several genes were specifically induced in the
recovered chimpanzee during the early phase of infection but not
in those chimpanzees with chronic infection. Two of the genes are
interleukin enhancer binding factor 3 (ILF3) and cytotoxic
granule-associated RNA binding protein (TIA1). This difference
was also confirmed by quantitative RT-PCR (Fig. 2). Both of them
are related to cellular immune response and may potentially
herald the emergence of a robust T-cell response later. The other
genes could be functionally clustered into cell growth/signal
transduction pathways. Genes such as FOSB, JUN, JUNB, and
ID2 (Tables 1 and 2) are typically associated with the immediate
early genes during liver regeneration [18,19]. Several studies
reported that ID2 (Inhibitor of DNA binding or Differentiation)
protein, a helix-loop-helix transcription factor, has important roles
in cell growth, differentiation and angiogenesis [20,21]. ID2 is also
essential for NK lineage commitment from bipotent progenitors of
both T and NK cells [22]. Other up-regulated genes including
EGR1, ETR101, CDK9 and RelA, are also related to cell growth
and proliferation [23–25]. Induction of EGR1 and ETR101 is also
part of the early proliferative response in the liver. In addition,
EGR1 is involved in the induction of FasL in T cells [26] and the
ETR101 has been implicated in T cell proliferation and
maturation [27]. These two genes might represent the induction
of a successful T cell response against HCV in chimpanzee X0190
but not in X0142 and X0234. The induction of these genes may
signify the initial phase of hepatocyte injury and proliferation,
despite the absence of aminotransferase elevation and liver
pathology during this stage of infection. This observation has
implication with respect to the induction of adaptive immunity
that is important for the subsequent control of viral infection. This
pattern of gene expression in the liver may represent a successful
‘‘danger signal’’ that has been proposed to be a trigger for adaptive
immunity. The lack of induction of these genes in chimpanzees
Figure 1. Chimpanzee inoculation and biopsy schedule. Chimpanzees were inoculated with RNA transcript of the molecular clone HCV-CG1b
or infectious serum from the same clone (#). The course of infection has been described previously (Thomson et al., 2001). The level of viremia is
shown as either positive (+) negative (2). Biopsy samples were taken at various time points after inoculation (Q) and used for microarray analysis
X0190, X0234 and X0142). RNA samples from weeks 8 and 10 of X0190 were not of adequate quality for microarray analysis.
doi:10.1371/journal.pone.0003442.g001
Hepatic Gene Expression
PLoS ONE | www.plosone.org 4 October 2008 | Volume 3 | Issue 10 | e3442that progress to chronic infection may actually represent a failure
to amplify anti-viral T-cell response. This intriguing hypothesis
awaits further studies to clarify the role of these genes during HCV
infection.
During acute HCV infection, a rapid IFN response limits virus
replication and spread in the liver until virus-infected hepatocytes
are cleared by specific T-cell immune response [3]. Analysis of
gene expression patterns during the viral clearance phase of
chimpanzee X0190 reveals the intrahepatic induction of cellular
immune response. This is particularly evident with markers of
CD8+ T cell response including granzyme A, CD8 antigen, T cell
receptors, and interferon-gamma (Table 3). On the other hand,
fewer of these genes were induced and at a lower magnitude in
chimpanzees with chronic infection. These findings are consistent
with a recent study on hepatic gene expression in chimpanzees
during acute HCV infection [2,6], and support the importance of
T cell immune response in controlling HCV infection [28–
33,12,34,7]. Other genes that were preferentially induced during
the clearance phase are diverse. They do not overlap with those
genes induced during the early phase of infection and may
Table 2. Genes induced during the early phase of self-limited infection as defined by average expression values.
Title Clone description UG cluster
Self-limited
infection
a
Persistent
infection
a
Ratio of
induction
FOSB FBJ murine osteosarcoma viral oncogene homolog B Hs.75678 7.54 0.77 9.77
DCT Dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-related protein 2) Hs.301865 6.55 0.69 9.44
SMARCB Actin dependent regulator of chromatin (SWI/SNF related) Hs.159971 6.04 0.64 9.41
EGR1 Early growth response 1 Hs.738 2.50 0.30 8.20
ETR101 Immediate early protein Hs.737 8.02 1.19 6.75
RPS4Y Ribosomal protein S4, Y-linked Hs.180911 8.46 1.40 6.02
JUN v-jun avian sarcoma virus 17 oncogene homolog Hs.78465 3.99 0.76 5.21
CYP1A1 Cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1 Hs.72912 2.18 0.48 4.51
SCYA3 Small inducible cytokine A3 (homologous to mouse Mip-1a) Hs.73817 1.23 0.29 4.28
PEX1 Peroxisome biogenesis factor 1 Hs.99847 3.68 0.90 4.09
KIAA0855 Golgin-67 Hs.182982 2.01 0.54 3.75
SARS Seryl-tRNA synthetase Hs.4888 1.13 0.31 3.68
GLO1 Glyoxalase I Hs.75207 4.14 1.14 3.63
ITGA6 Integrin alpha 6 Hs.227730 4.79 1.35 3.55
DUSP1 Dual specificity phosphatase 1 Hs.171695 2.31 0.68 3.41
PRNP Prion protein (p27–30) Hs.74621 2.79 0.87 3.21
RUVBL2 RuvB (E coli homolog)-like 2 Hs.6455 1.80 0.58 3.10
SCYA3L1 Small inducible cytokine A3-like 1 Hs.274535 0.97 0.31 3.10
TRF4 Topoisomerase-related function protein 4-1 Hs.225951 1.73 0.57 3.03
CALML3 Calmodulin-like 3 Hs.239600 2.96 1.01 2.94
GCN1L1 GCN1 (general control of amino-acid synthesis 1, yeast)-like 1 Hs.75354 1.58 0.55 2.89
SCD Stearoyl-CoA desaturase (delta-9-desaturase) Hs.119597 1.16 0.40 2.88
ATP2B2 ATPase, Ca++ transporting, plasma membrane 2 Hs.89512 1.40 0.49 2.86
CYP4F3 Cytochrome P450, subfamily IVF, polypeptide 3 (leukotriene B4 omega hydroxylase) Hs.106242 2.94 1.05 2.80
COL7A1 Collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive) Hs.1640 1.58 0.57 2.78
SLC6A3 Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 Hs.406 2.57 0.95 2.70
KLF4 Kruppel-like factor 4 (gut) Hs.7934 2.23 0.83 2.67
ILF3 Interleukin enhancer binding factor 3, 90 kD Hs.256583 2.63 1.00 2.62
ID2 Inhibitor of DNA binding 2 Hs.180919 2.64 1.02 2.58
ZNF216 Zinc finger protein 216 Hs.3776 1.07 0.41 2.57
NR1I2 Nuclear receptor subfamily 1, group I, member 2 Hs.118138 1.89 0.74 2.56
TIA1 TIA1 cytotoxic granule-associated RNA-binding protein Hs.239489 2.40 0.94 2.56
CDK9 Cyclin-dependent kinase 9 (CDC2-related kinase) Hs.150423 1.66 0.66 2.52
RELA v-rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa
light polypepti
Hs.75569 1.79 0.71 2.52
EPHX2 Epoxide hydrolase 2, cytoplasmic Hs.113 2.50 1.00 2.51
CYP4F2 Cytochrome P450, subfamily IVF, polypeptide 2 Hs.101 1.99 0.79 2.51
aAverage expression values of biopsies taken during the 1
st 8 weeks of infection.
Bold-face genes are also in Table 1.
doi:10.1371/journal.pone.0003442.t002
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during viral clearance. All these genes returned to baseline
expression after viral clearance. In contrast, many ISGs remained
elevated in chimpanzees with chronic infection, indicating an
ongoing type I IFN response to persistent HCV infection.
In this study, molecular profiling of gene expression patterns in
chimpanzees with serial liver biopsies during the course of
infection provides valuable information on the potential mecha-
nisms of viral clearance and persistence. Although the number of
animals is small, we are able to define a unique gene expression
pattern associated with viral clearance and demonstrate the
potential importance of induction of certain genes in a ‘‘successful’’
anti-HCV response. IFN-stimulated genes (ISGs) are induced
similarly regardless of the outcome of infection. Early induction of
a set of genes associated with cell proliferation and immune
activation appears to be involved in subsequent viral clearance.
Furthermore, evidence for a strong intrahepatic induction of
cellular immune response in chimpanzees associated with self-
limited infection is present. These findings support the importance
of T-cell immune response in controlling HCV infection.
Additional studies in other chimpanzees or humans with well-
characterized course of acute infection are necessary to confirm
these observations.
Materials and Methods
Animals
Chimpanzees (Pan troglodyte) were housed at the Southwest
Foundation for Biomedical Research, an Association for Assess-
ment and Accreditation of Laboratory Animal and Care
(AAALAC)-accredited facility, and the study protocol was
approved by the Institutional Animal Care and Use Committee
at the Foundation and by the Interagency Animal Model
Committee at the National Institutes of Health. Three chimpan-
zees (X0190, X0142 and X0234) were infected with HCV CG1b
strain, either by intrahepatic inoculation of HCV RNA or HCV-
positive serum, as described previously [16]. One animal X0190
recovered from the infection and the other two (X0142 and
X0234) developed chronic infection. The infection courses of all
three chimpanzees have been described in detail previously
[16,17] and summarized in Fig. 1 with time points of liver biopsy.
Another chimpanzee X6412 was infected with H77 1a strain and
developed chronic infection [35]. Serial liver biopsies of this
chimpanzee were provided by Stephen Feinstone of FDA.
RNA extraction and microarray expression analysis
RNA was isolated from liver biopsies (about 20 mg of liver
tissue which gives 10–15 mg of total RNA) of the chimpanzees.
Deposition cDNA microarrays containing 8703 features were
generated from IMAGE clones (ResGen, Huntsville, AL) as
described previously [36,37]. Liver biopsies were extracted directly
with Trizol (Invitrogen, Carlsbad, CA) and Dounce homogeniza-
tion. Following chloroform extraction, RNA samples were further
purified with RNeasy columns (Qiagen, Valencia, CA). 5–20 mg
total RNA was typically isolated from each liver biopsy and 5 mg
of RNA was amplified using a RiboAmp protocol (Arcturus
Bioscience Inc, Mountain View, California). A single round of
amplification yielded approximately 60 mg of polyA-selected
RNA, of which 2.5 mg was labeled by using the CyScribe first-
strand cDNA and labeling protocol (Amersham/Pharmacia,
Table 4. Genes induced during the clearance phase of self-limited infection as defined by average expression values.
Title Clone description UG cluster
Self-limited
infection
a
Persistent
infection
b
Ratio of
induction
RPS4Y Ribosomal protein S4, Y-linked Hs.180911 12.66 1.64 7.72
GLO1 Glyoxalase I Hs.268849 4.07 0.75 5.41
NPTX1 Neuronal pentraxin I Hs.84154 1.45 0.40 3.59
RI58 Retinoic acid- and interferon-inducible protein (58 kD) Hs.252839 2.40 0.70 3.42
UK114 Translational inhibitor protein p14.5 Hs.18426 2.00 0.59 3.40
AMHR2 Anti-Mullerian hormone receptor, type II Hs.437877 0.97 0.30 3.19
CD8B1 CD8 antigen, beta polypeptide 1 (p37) Hs.2299 5.57 1.76 3.16
KLRB1 Killer cell lectin-like receptor subfamily B, member 1 Hs.169824 3.89 1.24 3.13
APOF Apolipoprotein F Hs.2388 1.00 0.32 3.12
KIAA0855 Golgin-67 Hs.182982 1.60 0.54 2.95
TSNAX Translin-associated factor X Hs.96247 1.81 0.63 2.89
FKBP5 FK506-binding protein 5 Hs.7557 2.69 0.94 2.87
NNMT Nicotinamide N-methyltransferase Hs.364345 2.07 0.76 2.73
NUP153 Nucleoporin 153 kD Hs.146449 1.95 0.72 2.71
SOCS3 Supressor of cytokine signaling 3 Hs.436943 2.54 0.94 2.69
CD3D CD3D antigen, delta polypeptide Hs.95327 6.44 2.42 2.66
CALML3 Calmodulin-like 3 Hs.239600 3.37 1.28 2.63
ARF3 Human ADP-ribosylation factor Hs.22012 1.40 0.54 2.58
GZMA Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated
serine esterase 3)
Hs.90708 6.48 2.56 2.53
aExpression value of biopsy taken at 13 weeks of infection.
bAverage expression values of biopsies taken during the 10 and 12 weeks of infection.
Bold-face genes are also in Table 1.
doi:10.1371/journal.pone.0003442.t004
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PLoS ONE | www.plosone.org 8 October 2008 | Volume 3 | Issue 10 | e3442Figure 2. Real-time PCR quantification of candidate genes involved in viral clearance and persistence. TaqMan real-time PCR was
performed as described in Materials and Methods. The y-axis shows the relative unit of a given gene normalized to GAPDH and 18s rRNA. Data are
expressed as means6SEM. In all cases, average values obtained during the first eight weeks of infection were compared between recovered (X0190)
and chronically infected chimpanzees (X 0234, X0142 and X6412). * P,0.05,* *P,0.01, *** P,0.01, **** P,0.005.
doi:10.1371/journal.pone.0003442.g002
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produce Cy-5 labeled cDNA while Cy-3 labeled cDNA was made
in a similar manner from pre-infection or uninfected reference
liver RNA. Individual Cy-5 labeled samples were mixed with the
Cy-3 labeled reference and hybridized overnight at 65uCi na n
aqueous based hybridization solution. Detailed RNA isolation,
labeling and hybridization protocols are available at http://
research.nhgri.nih.gov/microarray/. Slide images were acquired
by an Agilent scanner (Agilent Technologies, Palo Alto, CA). Gene
assignments and expression data were extracted using the DeArray
Suite [38] for IPLab spectrum. The resulting data was download-
ed to FileMaker Pro (FileMaker Inc., Santa Clara, CA). Phenotype
averaging was performed using the BRB array tools, developed by
the Biometrics Research Branch, Division of Cancer Treatment
and Diagnosis and available to download on the web: http://linus.
nci.nih.gov/BRB-ArrayTools.html
Real-time Quantitative PCR
Real-time quantitative PCR was used to confirm the microarray
findings. Complementary DNA (cDNA) was synthesized from total
RNA (isolated from liver biopsy samples) with First-strand cDNA
Synthesis System (Marligen Biosciences, Ijamsville, MD). In
addition, we analyzed serial liver biopsy samples from a
chronically infected chimpanzee (X1602, infected with genotype
1a H77 strain) by TaqMan PCR quantification of selected genes of
interest. The primers and probes used were obtained from Gene
Expression Assays (Applied Biosystems, Foster City, CA). Each
reaction was performed in duplicate, and all samples were
standardized using the internal control glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) gene and 18S rRNA. Reactions
were set up with 12.5 mL TaqMan universal PCR master mix,
cDNA template, and 1.25 mL primers and probe mix in a final
volume of 25 mL. Reactions were performed on an iCycler iQ
Multicolor Real-Time Detection System (Bio-Rad, Hercules, CA)
with the following reaction conditions: 95uC for 10 min, followed
by 40 cycles of 95uC for 20 sec, 60uC for 1 min, and additional
incubation at 68uC for 10 min.
Statistical Analysis
The overall significance was assessed by 1-way ANOVA and
significant difference between groups was assessed by the Student’s
t-test.
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